Probatebeta
Company

Lakefront Biotherapeutics

As of the edition of 20 October 2026, Lakefront Biotherapeutics runs 23 drugs, 1 of them marketed; it is on route A at 6 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Marketed1
Active2
Went quiet10
Stopped8
Status not established2
Total23

Marketed drugs and when their US protection ends

DrugUS protectionRoute B rows
Filgotinibnone listed3

A route B row is one company at one target.

Where it needs a new molecule

Route A at 6 targets, route B at 0 targets.

Three of its 6 rows, by target and route
TargetRoute
ADAMTS5 A disintegrin and metalloproteinase with thrombospondin motifs 5Route A
MAPKAPK5 MAP kinase-activated protein kinase 5Route A
FFAR2 Free fatty acid receptor 2Route A

All 6 rows on route A or B

In the product

6 company-target rows on route A or B; 3 are not shown here, and no score is.

See all 6 targets where Lakefront Biotherapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.

Where its trials are

  • Skin and connective tissue: 21 trials led
  • Bones, joints and muscles: 16 trials led
  • Immune system: 15 trials led

Targets where Lakefront Biotherapeutics has drugs

Other companies active in skin and connective tissue